Atopic Dermatitis study: 1.5% QLM3003 ointment vs 2% QLM3003 ointment
Official title Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
ClinicalTrials.gov ID: NCT06880276
What this study is testing
What is 1.5% QLM3003 ointment?
This is an investigational topical cream being studied as a potential treatment for mild to moderate atopic dermatitis.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if QLM3003 ointment improves skin symptoms after 8 weeks, measured by EASI 75 and IGA‑TS scores.
- Who it's for
- Adults or children with mild or moderate atopic dermatitis who can apply ointment twice daily.
- What's involved
- Participants will be randomly given either 1.5% QLM3003, 2% QLM3003, or a placebo ointment and apply it twice a day for 8 weeks, with visits to assess skin improvement.
- Time commitment
- The trial lasts 8 weeks, with scheduled visits for assessments and ointment dispensing during that period.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Male or female, 18-75 years old
- The diagnosis of atopic dermatitis (AD) during screening meets the Hanifin⁃Rajka standard, and the history of AD/ eczema ≥1 year before screening.
You likely can't join if
- people with comorbidities or other conditions that may interfere with the assessment of the investigational drug or the study disease, as determined...
- Patients whose current AD disease status was assessed by the investigators to be unstable (spontaneous improvement or rapid deterioration) were not...
- Patients who have received a marketed or investigational biologic for the treatment of AD, such as Dupilumab, within 3 months before baseline or...
- Patients who had received systemic or topical JAK inhibitor therapy, including but not limited to Tofacitinib, Ruxolitinib, Upadacitinib...
The study team makes the final eligibility decision.
Where it is enrolling
- Shenyang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Shenyang, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.